蛋白冠原位调控增强肿瘤靶向19F MRI和联合治疗
In Situ Regulation of Protein Corona for Enhanced Tumor-targeted 19F MRI and Combined Therapy
蛋白冠原位调控增强肿瘤靶向19F MRI和联合治疗 |
| 李睿鹥, 李莎, 徐秋怡, 隋美菊, 陈世桢 |
|
In Situ Regulation of Protein Corona for Enhanced Tumor-targeted 19F MRI and Combined Therapy |
| LI Ruiyi, LI Sha, XU Qiuyi, SUI Meiju, CHEN Shizhen |
| 图2 PP@BSA-TAFeIII NPs的表征. (a) PP NPs、PP@BSA NPs、PP@BSA-TAFeIII NPs的TEM图；(b) PP@BSA-TAFeIII NPs的TEM mapping图；(c, d) PP NPs、PP@BSA NPs、PP@BSA-TAFeIII NPs的(c)水合粒径分布图和(d)ζ电势； (e)不同纳米颗粒（PFCE浓度为2 mmol/L）的紫外可见吸收光谱；(f) PP@BSA-TA NPs和PP@BSA-TAFeIII NPs（PFCE浓度为100 mmol/L）的红外吸收光谱 |
| Fig. 2 Characterization of PP@BSA-TAFeIII NPs. (a) TEM images of PP NPs, PP@BSA NPs and PP@BSA-TAFeIII NPs; (b) TEM mapping image of PP@BSA-TAFeIII NPs; (c) Size distribution and (d) zeta potential of PP NPs, PP@BSA NPs and PP@BSA-TAFeIII NPs; (e) UV-vis absorption spectra of different nanoparticles (concentration of PFCE is 2 mmol/L); (f) FT-IR spectra of PP@BSA-TA NPs and PP@BSA-TAFeIII NPs (concentration of PFCE is 100 mmol/L) |
|
|